BWX Technologies, Inc. (BWXT) - 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for BWX Technologies, Inc. for the fiscal year ended December 31, 2024. BWXT is a specialty manufacturer of nuclear components, a developer of nuclear technologies, and a service provider with over 100 years of operating history. The company operates in two reportable segments: Government Operations (naval nuclear components, reactors, fuel, and site management for the U.S. Government) and Commercial Operations (commercial nuclear components, fuel, and medical radioisotopes). The U.S. Government accounted for approximately 76% of total consolidated revenues in 2024.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $2,703.7 million | $2,496.3 million | +8.3% |
| Operating Income | $380.6 million | $383.1 million | -0.6% |
| Net Income (Attributable to BWXT) | $281.9 million | $245.8 million | +14.7% |
| Diluted EPS | $3.07 | $2.68 | +14.6% |
| Operating Cash Flow | $408.4 million | $363.7 million | +12.3% |
| Total Debt (Long-term + Current) | $1,055.5 million | $1,209.7 million | -12.7% |
| Backlog (Year-End) | $4,842.5 million | $3,998.0 million | +21.1% |
| Liquidity (Cash + Available Borrowing) | $797.7 million | $649.1 million | +22.9% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased by $207.3 million, driven by a $151.7 million increase in Government Operations (higher volume in naval nuclear components and advanced technologies) and a $57.6 million increase in Commercial Operations (higher revenues in nuclear components and medical radioisotopes).
- Operating Income: Despite revenue growth, total operating income decreased slightly by $2.5 million. Segment operating income increased ($5.5 million in Government; $9.3 million in Commercial), but this was offset by a $14.9 million increase in Unallocated Corporate expenses, primarily due to IT infrastructure transformation initiatives ($9.5 million) and due diligence costs ($4.5 million).
- Net Income: Net income rose significantly due to a reduction in the effective tax rate (19.0% in 2024 vs. 23.4% in 2023) driven by R&D tax credits, and a decrease in net periodic benefit costs (a gain of $0.8 million in 2024 vs. a loss of $20.9 million in 2023).
- Debt Reduction: The company reduced net borrowings of long-term debt by $75.0 million, utilizing strong operating cash flows to pay down the Revolving Credit Facility.
Guidance, Outlook, and Risks
- Backlog Outlook: Management expects to recognize approximately 48% of the $4.84 billion backlog by the end of 2025.
- Acquisitions:
- Completed: Acquired Aerojet Ordnance Tennessee, Inc. (A.O.T) on January 3, 2025, for approximately $105.5 million to enhance advanced materials capabilities.
- Pending: Agreed to acquire Kinectrics, Inc. for approximately CAD 782.7 million (approx. $525 million USD equivalent), expected to close mid-2025. This will expand lifecycle management services and isotope production.
- Key Risks:
- Government Funding: 76% of revenue relies on U.S. Government contracts, subject to annual appropriations, budget cuts, and potential shutdowns.
- Trade Policy: Potential tariffs on imports from Canada (where medical radioisotopes are manufactured) could impact gross margins if costs cannot be passed to customers.
- Contract Estimates: Revenue is recognized over time; changes in cost estimates for long-term contracts can cause volatility in operating income.
- Cybersecurity: As a government contractor, the company faces heightened cyber threats which could disrupt operations or compromise sensitive data.
Investor Verification Checklist
- Contract Adjustments: Verify the sustainability of revenue growth given the reliance on contract adjustments (which added $37.9 million to revenue in 2024) and the risk of future cost overruns on fixed-price contracts.
- Acquisition Integration: Monitor the closing and integration of the Kinectrics acquisition and the impact of the A.O.T. acquisition on the Government Operations segment.
- Corporate Expenses: Track the trajectory of Unallocated Corporate expenses, specifically the IT transformation costs, to ensure they do not continue to erode operating margins.
- Backlog Funding: Assess the $387.4 million of unfunded backlog related to U.S. Government contracts and the risk of funding delays or cancellations.
- Debt Covenants: Confirm continued compliance with the Credit Facility covenants (leverage ratio max 4.00:1.00) as the company pursues further acquisitions.